ProMIS Neurosciences is trading 5.36% lower at $8.86, with no clear catalyst identified. - The decline is from the October 5 close of $9.37; no volume or trading-activity figures were provided. - On October 6, the company announced Ivana Rubino’s appointment as Chief Commercial Officer. PMN310 data is expected in Q1 2027; the announcement does not explain the decline. - Major indices are higher, so broader-market weakness does not account for the move.